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Abstract
Objective. To summarize evidence regarding the effectiveness of MTX in the treatment of childhood
autoimmune chronic uveitis (ACU).
Methods. A systematic search of articles between January 1990 and June 2011 was conducted using
EMBASE, Ovid MEDLINE, Evidence-Based Medicine Reviews—ACP Journal Club, the Cochrane Library
and EBM Reviews. Studies investigating the efficacy of MTX as a single immunosuppressant medication in
the treatment of ACU refractory to therapy with topical treatment and/or systemic treatment in children
(416 years) were eligible for inclusion. The primary outcome measure was the improvement of intraocular
inflammation, expressed as Tyndall, as defined by the Standardization of Uveitis Nomenclature working
group criteria. The effect measure for each study was the proportion of people classified as responders.
We determined a combined estimate of the proportion of children in the eligible studies responding
to MTX.
Results. The initial search identified 246 articles of which 52 were potentially eligible. Nine eligible articles,
all retrospective chart reviews, remained in the analysis. The number of children in studies ranged from
3 to 25, and the dose of MTX varied from 7.5 to 30 mg/m2. Altogether, 95 of 135 children responded to
MTX. The pooled analysis suggested that MTX has a favourable effect in the improvement of intraocular
inflammation: the proportion of responding subjects was 0.73 (95% CI 0.66, 0.81).
Conclusion. Although randomized controlled trials are needed, the available evidence supports the use of
MTX in the treatment of childhood ACU: approximately three-quarters of patients on MTX can expect
improvement in intraocular inflammation.
Key words: methotrexate, autoimmune chronic uveitis, childhood, refractory uveitis.
Introduction
Non-infectious uveitis in childhood, with an incidence and
prevalence estimated at 5 and 30 per 100 000, respect-
ively, is a serious disease, with the potential for signifi-
cant long-term complications and eventually blindness.
Although frequently associated with an underlying sys-
temic disease, e.g. JIA, Behc¸et’s disease, sarcoidosis
or tubulointerstitial nephritis, a significant number of
cases are idiopathic. In case of refractory uveitis, early
and aggressive immune-modulatory treatment, even in
children, seems a reasonable approach to control inflam-
mation, to achieve a CS-sparing effect and to decrease
the risk of sight-threatening ocular damage [1]. However,
there is much less experience and fewer cumulative
data in treating children with uveitis or other inflammatory
ocular diseases [2], and a lack of randomized controlled
trials (RCTs) means that treatment with immunosup-
pressive drugs is supported only at evidence level III:
expert opinion, clinical experience or descriptive studies
[3]. MTX, a folate analogue inhibiting the enzyme
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dihydrofolate reductase, is the most frequently used im-
munosuppressive in the paediatric uveitis population, but
the lack of evidence from RCTs limits our understanding
of effectiveness, the optimal time to start therapy and op-
timal duration [2, 3]. Due to its common use as
steroid-sparing treatment in children, the purpose of this
review is to summarize the best available evidence to date
regarding the effectiveness of MTX in childhood autoim-
mune chronic uveitis (ACU).
Methods
Eligibility criteria
The following criteria were used to select eligible studies:
(i) patients had vision-threatening non-infectious autoim-
mune uveitis; (ii) autoimmune uveitis was refractory to
therapy with topical and/or systemic treatment, thus
showing a chronic disease course with regard to steroid
therapy according to the Standardization of Uveitis
Nomenclature (SUN) criteria definition, that is persistent
uveitis characterized by relapse within 3 months after dis-
continuation of therapy; (iii) patients had disease onset at
or before 16 years of age; (iv) patients received MTX as
single immunosuppressant medication for the treatment
of uveitis; (v) outcome measures to assess the effective-
ness of MTX were collected according to the SUN criteria
[4]. Intraocular inflammation was considered active or un-
controlled if the inflammatory activity was grade 51+ at
any examination. Uveitis was defined as improved, and
MTX as successful, when its activity decreased by two
steps in the level of inflammation (anterior chamber cells
and/or vitreous haze) or decreased to grade 0 [4]. For
studies not completely adherent to the SUN criteria and
those performed before 2005, where possible, we retro-
spectively applied the SUN activity terminology with
regard to reported activity grading and only an activity
grade of 0 was considered as improved; (vi) studies
were published in English. Exclusion criteria were as fol-
lows: (i) the concomitant use of other immunosuppressant
agents in addition to MTX; (ii) starting time of MTX admin-
istration after 16 years of age; and (iii) lack of applicability/
adherence to the SUN working group criteria definition of
improvement in uveitis activity.
Outcome measures
The main outcome measure used to assess the effect of
MTX was the improvement of intraocular inflammation as
Tyndall (anterior chamber cells), according to the defin-
ition of improvement of the SUN working group criteria
[4]. As secondary outcomes, tapering and/or stopping
systemic steroid administration, improvement in visual
acuity post MTX treatment according to the SUN working
group criteria, discontinuation of MTX, time to remission
(the duration of MTX treatment needed to achieve
remission-inactive disease), time on remission on therapy
(the duration of on-going/persistent remission, while MTX
treatment continued) and time on remission off therapy
(the period with on-going/persistent remission after
discontinuing MTX treatment), and safety of administered
drug were considered.
Information sources
Publications were retrieved using a computerized search
of the following databases: EMBASE, Ovid MEDLINE,
Evidence-Based Medicine (EBM) Reviews—ACP Journal
Club, EBM Reviews—Cochrane Central Register of
Controlled Trials, EBM Reviews—Cochrane Database
of Systematic Reviews and EBM Reviews—Database of
Abstracts of Reviews of effects. Publications between
January 1990 and June 2011 were included.
Search strategy
Databases were searched with the key words chronic
uveitis or chronic iridocyclitis or recurrent uveitis or refrac-
tory uveitis or non-infectious uveitis or autoimmune uveitis
or inflamma$ ocul$ or inflamma$ eye and were crossed
with Metotrexate or Methotrexate or MTX. Of note, we
did not include children, age or age limits in the search
as MeSH terms because we may have been able to ex-
tract, if possible, a subcohort of children from studies
including both children and adults. No limitation with
regard to the type of the study was entered. This strategy
excluded records related to infectious and/or suppurative
uveitis.
Study selection
Two reviewers (G.S., P.P.) independently screened the
retrieved titles and abstracts and excluded duplicates
and those obviously irrelevant. If the information in the
abstracts was insufficient to make a decision, full papers
were retrieved. Full papers of the selected articles were
examined to determine whether they satisfied the criteria
(G.S.) and then confirmed by a second reviewer (P.P.). The
references of all eligible articles including reviews, expert
opinion papers and systematic reviews were manually
searched for potentially eligible publications. During con-
sensus meetings (G.S., P.P., G.J., G.M.), disagreements
of selections were resolved. In addition, we contacted au-
thors of studies to determine whether data on an eligible
subgroup were available.
Data extraction and items
Data were extracted by a single reviewer (G.S.) using a
standard form, and checked by a second reviewer (P.P.).
The data items extracted were as follows: study design,
study start/end dates, length of follow-up, aim of the
study, characteristics of participants (number of children,
gender, age and associated conditions), dose of MTX and
all outcome measures.
Statistical analysis
A meta-analysis was conducted to determine a combined
estimate of the proportion of children in the eligible stu-
dies responding to MTX. The effect measure for each
study was the proportion of participants classified as re-
sponders on MTX, with respect to intraocular inflamma-
tion [p(i)], where i refers to study i. If not provided in the
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original manuscript, we calculated a 95% CI for the
observed proportion. We tested for heterogeneity be-
tween the effect estimates from studies by conducting
Cochrane’s 2 test, which has k 1 degrees of freedom,
where k is the number of studies. In combining estimates,
each study estimate was given a weight as the inverse of
the proportion variance {i.e. n(i)/(p(i)[1p(i)] for study i},
where n(i) is the number of persons in study i. The com-
bined estimate (p) and its standard error were then calcu-
lated in order to provide a 95% CI for this combined
estimate of the proportion of patients improving.
Results
A total of 246 articles were identified by searches of data-
bases, and, from these, 194 were excluded by examin-
ation of their titles and abstracts. Excluded studies were
mainly studies not reporting paediatric cases, duplicates,
studies on diseases other than autoimmune non-
infectious uveitis, studies on overall mortality among
patients receiving immunosuppressive treatment and stu-
dies on drugs other than MTX. Full text of the remaining
52 studies and 20 additional papers obtained by screen-
ing of their references were scrutinized. From the selec-
tion process, a total of nine relevant articles were deemed
eligible. The other 63 potential eligible papers were
excluded because they were reviews and/or expert opin-
ion papers, they had no information regarding MTX effi-
cacy as single immunosuppressive therapy, it was not
possible to extract data on children from an overall
study population and this was not available from authors,
they did not include data on the principal outcome and/or
were non-adherent to SUN criteria.
Table 1 summarizes data items from each eligible
paper. All of the included studies were retrospective chart
reviews, with a median follow-up time of 22.5 months
(range 196). The number of children in these studies
ranged from 3 to 28, providing a total of 135 children.
It was not possible to extract detailed childhood descrip-
tive data from some of the included studies: regarding
gender from three studies [6, 9, 11] and age at uveitis
onset from one [11]. Twenty-three subjects were male,
46 were female, and the median age of uveitis onset
was 8 years (range 1.816). Chronic uveitis was asso-
ciated with JIA (n= 121), early-onset sarcoidosis (n= 5)
and tubulointerstitial nephritis (n= 3); the remaining were
idiopathic. Six of the nine studies, with a total of 119 pa-
tients, were exclusively in JIA patients. Four studies re-
ported a MTX dose between 7.5 and 30 mg/m2, weekly,
with 15 mg/m2 the most commonly used dose. Four stu-
dies did not report the dose per m2 of body surface and
the MTX dose varied from 7.5 to 40 mg/week (median
dose/week 12.5 mg); in one study MTX was administered
at a dose of 0.51 mg/kg, weekly [13].
All included studies reported our main outcome meas-
ure: the improvement of intraocular inflammation as
Tyndall (anterior chamber cells), according to the defin-
ition of improvement of the SUN working group criteria.
Altogether, 95 children out 135 included responded to the
treatment. The pooled analysis suggested that MTX has a
favourable effect in the improvement of intraocular inflam-
mation: 0.73 (95% CI 0.67, 0.81) was the combined esti-
mate of the proportion of subjects improving on MTX
(Fig. 1), and there was no evidence of heterogeneity
across studies (P= 0.5). In a subanalysis including only
those studies exclusively on JIA the estimate was very
similar (0.74, 95% CI 0.67, 0.82).
Not all of the secondary outcome variables were pre-
sent in each study and often were reported in diverse
ways; thus we were not able to perform effect size ana-
lyses on these. All eligible papers, except Samson et al.
[11], which did not report separate childhood data, had
information regarding MTX discontinuation: MTX was dis-
continued in 35 (32.7%) out of 107 children, due to per-
sistent remission in 21 (19.6%), lack of efficacy in 7 (6.5%)
and adverse events in the remaining 7. Time to remission
on MTX was described in 5 [57, 9, 12] out of 9 eligible
papers: 45 (73.8%) out of 61 children obtained remission
over a median time of 3.5 months (range 112). In add-
ition, Foeldvari et al. [7] along with Weiss et al. [13]
reported that 25/29 children remained on remission on
MTX for a median time of 10.6 months (range 327).
However, Heiligenhaus et al. [6] reported that remission
as per SUN criteria was not obtained in any of the patients
during a follow-up period of 27.6 months, and Foeldvari
showed that, after MTX discontinuation, 2 of 6 children
experienced uveitis flares 3 and 8 months later [7].
During MTX administration, tapering and/or stopping sys-
temic steroid administration was possible in 22 of 23 chil-
dren, but data were available from only four papers [5, 6,
8, 12]. Data regarding visual outcome have been reported
in three articles [6, 8, 10]: 11 of 13 children (84.6%)
showed improvement or stable visual acuity post MTX
treatment. We could not extract information from
Heiligenhaus study [6] because some of their patients
(7 of 35) received MTX along with other immune-
modulatory drugs. Among 107 MTX exposed children
(data regarding children were not available from Samson
et al.’s study [11]), 21 (19.6%) experienced adverse events
due to MTX administration: 10 children had
gastrointestinal discomfort, mostly nausea, 6 showed ele-
vation of liver enzymes, reversible in 3, the remaining 5
children presented both nausea and increased liver func-
tion tests.
Discussion
We have estimated that the overall probability of improve-
ment of intraocular inflammation in children affected by
refractory ACU treated with MTX is 73%. The estimates
of response were similar across studies, in particular
when we considered those studies (6 of 9) that included
only patients with JIA. However, several caveats have to
be discussed before drawing firm conclusions from our
systematic review. We recognize RCTs as the gold stand-
ard in assessing drug effectiveness; thus because none
are available we acknowledge the generally poor quality of
evidence. The majority of eligible studies only included
patients with JIA, along with other diseases. However,
the small number of the available studies meant we
www.rheumatology.oxfordjournals.org 827
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could not consider results separately according to the
underlying disease. We did not include studies when it
was not possible extract information on eligible children
from those studies (e.g. a study of Behc¸et’s disease [14]).
This affected several large studies on this topic—e.g. Yu
et al. [15]. We contacted authors to determine whether
information was specifically available on children to
allow the study to be included, but this did not result in
any additional study being eligible. The main outcome
measure used in this systematic review might be con-
sidered another limitation: the definition of improvement
of the SUN working group criteria [4] is not assessed in
childhood, and therefore not validated for childhood use.
However, it is otherwise the only standardized measure
available for assessing differences in uveitis inflammation,
and thus to date, the only item able to compare different
studies, across different decades and different childhood
diseases. The different steroid use, as systemic adminis-
tration rather than eye drop, significantly changed over the
considered time period, might be an additional potential
caveat.
There are no clear recommendations for MTX use in
childhood, even though it is largely used in chronic uveitis,
mostly when associated with JIA [2, 3, 1620]. The results
of this review could be helpful for clinicians in judging the
utility of this treatment and its effect size on visual prog-
nosis, as well in making a therapeutic decision based on
current available evidence. Our findings support the clin-
ical use of MTX for refractory ACU in children. However, it
needs to be considered in the context that all the current
evidence is from retrospective chart reviews. The results
of this meta-analysis should prompt the conduct of
RCTs on this topic, involving paediatric rheumatologists,
ophthalmologists and pharmaceutical companies, to pro-
vide a higher quality evidence base.
Rheumatology key messages
. There are few cumulative data on treating children
with chronic uveitis.
. MTX seems an effective therapy for childhood
non-infectious uveitis associated with JIA and pos-
sibly other conditions.
. Randomized clinical trials in childhood ACU treat-
ment seem mandatory.
Disclosure statement: G.T.J. has received grants/research
support from Pfizer Inc, NY, USA. All other authors have
declared no conflicts of interest.
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